DDInter154 DDInter239
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Azelastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cilostazol
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Azelastine {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Cilostazol
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Doxylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Azelastine {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Azelastine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brivaracetam
Azelastine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Abiraterone
Abiraterone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Azelastine {u} (Compound) downregulates {v} (Gene) LAP3
LAP3 {u} (Gene) is downregulated by {v} (Compound) Cilostazol
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Azelastine {u} (Compound) causes {v} (Side Effect) Arthritis
Arthritis {u} (Side Effect) is caused by {v} (Compound) Cilostazol
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Azelastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Azelastine (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Azelastine (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Azelastine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Azelastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound) and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Azelastine (Compound) downregulates LAP3 (Gene) and LAP3 (Gene) is downregulated by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Azelastine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound) and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam